Supplemental Figure 2 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas
Year: 2023
Type: supplementary-materials
Abstract: Supplemental Figure 2. Dose modifications of Dacomitinib +/- Osimertinib (acquired resistance study).
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4365510668